美国达拉斯消息:据美国心脏协会(AHA)年会报告的早期临床试验结果表明,计划将市售的一种新的溶血栓剂与链激酶的效果相同,给药更方便,且作用时间长。此制剂为甲氧苯甲酰化纤维蛋白溶酶原链激酶激活因子复合物(APSAC),一次静脉内注射2～5分钟,血浆清除率的半寿期为90分钟。犹他大学的研究人员报告说,在纤维蛋白原恢复到正常前,此制剂保持最大有效作用至少4小时。 Dallas, United States: Early clinical trials reported at the annual meeting of the American Heart Association (AHA) showed that a new thrombolytic agent is commercially available that has the same effect as streptokinase and is more convenient and effective for longer periods of time. The formulation is the anisoylated plasminogen streptokinase activator complex (APSAC), with an intravenous injection of 2 to 5 minutes and a plasma clearance of 90 minutes. Researchers at the University of Utah reported that this formulation had the most effective effect for at least 4 hours before fibrinogen returned to normal.